Company / Working Capital
Cytek Biosciences, Inc. Working Capital History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$314.2M
FY2025
5-year range
$314.2M / $405.0M
FY2021-FY2025
Trend
-4.4%
vs FY2024
Sector context
#89 of 160
Health Care
What the data says
At $314M, Cytek Biosciences, Inc.'s working capital ranks #89 of 160 in the Health Care sector. Working Capital has declined for 3 consecutive years, from $405M in FY2022 to $314M in FY2025.
Based on SEC 10-K filings.
$314M in FY2025 with a 5-year CAGR of +11.5%.
Declined from $336M to $314M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -8.1%
- 5-Year CAGR
- +11.5%
- 10-Year CAGR
- -
Sector benchmark
#89 of 160 in Health CareTop 56% of 160This company $314.2M Sector average $757.1M
▼
-58.5% below sector average
Key checks
Key Insights
- Cytek Biosciences, Inc.'s working capital has declined for 3 consecutive years.
- 5-year CAGR of +11.5%, indicating consistent growth.
- In FY2025, working capital decreased 4.4% year-over-year.
- Ranks #89 out of 160 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $314.2M | -4.4% |
| FY2024 | $328.8M | -2.1% |
| FY2023 | $335.8M | -17.1% |
| FY2022 | $405.0M | +1.6% |
| FY2021 | $398.6M | +118.9% |
| FY2020 | $182.1M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026